Warnings about the potential threats of artificial intelligence (AI) technology have been coming from various industries. However, one of Britain’s largest drug firms, GlaxoSmithKline (GSK), believes that the use of cutting-edge AI could have a positive impact on the development of new medicines.
GSK has begun using AI to personalize its medical treatments for individual patients, which can increase the effectiveness of drugs. By analyzing massive quantities of data, AI has allowed GSK to speed up certain parts of the clinical trial process by up to five times.
The use of AI has also shown promise in increasing the success of new medicines in treating patients. For example, GSK used AI to identify different patient groups and predict their response to a new drug being developed for chronic hepatitis B. This could potentially increase the chances of success by up to seven times.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
